Pfizer CIFFREO Webinar

Pfizer’s Global Clinical Lead for Rare Neurological Diseases, Beth Belluscio, MD-PhD, and Debra Miller, Founder and CEO of CureDuchenne, sat down to educate the Duchenne community on Pfizer’s CIFFREO Trial – a phase 3 study to assess the safety and efficacy of their mini-dystrophin gene therapy in ambulatory boys with Duchenne.

Watch this webinar to learn more about the upcoming opening of US trial sites, trial design, safety considerations, key inclusion/exclusion criteria, and more. Pfizer’s presentation is followed by a thoughtful Q&A session with CureDuchenne’s Debra Miller.

Click to read: Pfizer’s Letter to the Duchenne Community, April 28, 2022

For more information visit: ciffreoduchennetrial.com and clinicaltrials.gov/ct2/show/NCT04281485  
Phone: 1-800-887-7002 
Email: PfizerClinicalTrialsInquiry@pfizer.com